Quick Dispatch:
Your tirzepatide cardiovascular trial Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide cardiovascular trial Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes ships.
Need Help?
Questions about tirzepatide cardiovascular trial Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide cardiovascular trial Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes in your area.
Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity
21.13
An Observational Study of Cardiovascular Outcomes of Tirzepatide vs Glucagon-Like Peptide-1 Receptor Agonists
21.87
In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%
27.37
Effects of tirzepatide on adjudicated cardiovascular events in
25.06
Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management - Abdul‐Hafez - 2026 - Endocrinology, Diabetes & Metabolism
23.57
CARDIOVASCULAR EFFICACY OF TIRZEPATIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: AN INDIVIDUAL PARTICIPANT DATA META-ANALYSIS OF 8 RANDOMIZED CLINICAL TRIALS
26.53
SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide
23.89
